Maze Therapeutics, Inc. (MAZE) Stock Forecast
MAZE analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.92 / 5 from 13 analysts
- Price target
- $61.50 average of analyst targets
- Upside to target
- +123.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.78
- 52-week range
- $22.39 – $51.84
MAZE analyst ratings
13 analystsNumber of analysts at each rating.
MAZE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MAZE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.75 | −$0.87 | −$0.56 | −$0.66 | −13.9% | 9 |
| Current fiscal year (2026) | −$2.74 | −$3.06 | −$2.07 | −$3.05 | +10.2% | 9 |
| Next fiscal year (2027) | −$3.22 | −$4.28 | −$2.31 | −$2.74 | −17.7% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MAZE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 11 |
| Current fiscal year (2026) | $20.0M | $20.0M | $20.0M | 0.0% | 12 |
| Next fiscal year (2027) | $8.1M | $0 | $60.0M | −59.5% | 12 |
MAZE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MAZE revenue: reported and forecast
MAZE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.75 | −$0.75 | −$0.75 | −$0.76 | −$0.75 | +0.4% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.67 | −$2.67 | −$2.73 | −$2.76 | −$2.74 | +2.5% | 1 up · 0 down |
| Next fiscal year (2027) | −$3.19 | −$3.19 | −$3.18 | −$3.30 | −$3.22 | +1.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MAZE earnings surprises
Reported EPS vs the consensus estimate for the last 7 quarters; MAZE beat in 5 of 7.
What analysts expect from MAZE
13 analysts cover Maze Therapeutics; their consensus rating is strong buy (4.92 on a 1–5 scale, where 5 is a strong buy). The average price target is $61.50, 123.4% above the latest close of $27.53. Analysts expect earnings of −$2.74 per share for 2026, +10.2% from a year earlier. For 2027 the average estimate is −$3.22 per share on revenue of $8.1 million. Maze Therapeutics beat the EPS estimate in 5 of the last 7 quarters.
Related: MAZE income statement, MAZE key metrics, MAZE chart. See the MAZE stock overview for the latest quote and news.
MAZE forecast FAQ
What is Maze Therapeutics's price target?
The average analyst price target for Maze Therapeutics is $61.50, 123.4% above the latest close of $27.53.
Is Maze Therapeutics a buy, hold or sell?
Of 13 analysts covering Maze Therapeutics, 12 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Maze Therapeutics's EPS forecast?
Analysts forecast −$2.74 per share for 2026 (range −$3.06 to −$2.07); for 2027 the estimate is −$3.22.
What is Maze Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $20.0 million, growth of 0.0%; for 2027 it is $8.1 million.
When does Maze Therapeutics report earnings?
Maze Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.78.
Does Maze Therapeutics usually beat earnings estimates?
Maze Therapeutics reported EPS at or above the analyst estimate in 5 of the last 7 quarters.